An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

Necchi Andrea; Giannatempo Patrizia; Raggi Daniele; Mariani Luigi; Colecchia Maurizio; Fare Elena; Monopoli Francesco; Calareso Giuseppina; Ali Siraj M.; Ross Jeffrey S.; Chung Jon H.; Salvioni Roberto

首页> 外文期刊>European urology >An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

【24h】

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

机译：单独的Open-Label Orcualized阶段2研究Durvalumab或与高级生殖细胞肿瘤患者（Apache）组合的Tremetimumab（Apache）：第一次计划中期分析的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2019年第1期|共3页
作者
Necchi Andrea; Giannatempo Patrizia; Raggi Daniele; Mariani Luigi; Colecchia Maurizio; Fare Elena; Monopoli Francesco; Calareso Giuseppina; Ali Siraj M.; Ross Jeffrey S.; Chung Jon H.; Salvioni Roberto;
展开▼
作者单位

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

Fdn Med Inc Cambridge MA USA;

Fdn Med Inc Cambridge MA USA;

Fdn Med Inc Cambridge MA USA;

Fdn IRCCS Ist Nazl Tumori Milan Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
专利

1. An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis [J] . Necchi Andrea, Giannatempo Patrizia, Raggi Daniele, European urology . 2019,第1期

机译：单独的Open-Label Orcualized阶段2研究Durvalumab或与高级生殖细胞肿瘤患者（Apache）组合的Tremetimumab（Apache）：第一次计划中期分析的结果
2. A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors [J] . Kyriakos P Papadopoulos, Frank Tsai, Omid Hamid, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：一项I期研究旨在评估durvalumab（MEDI4736）联合tremelimumab在晚期实体瘤患者中的安全性和抗肿瘤活性
3. A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR [J] . Siu L., Even C., Mesia R., International Journal of Radiation Oncology, Biology, Physics . 2018,第5期

机译：Durvalumab（d），Tremetimumab（t），或d plus t的随机，开放标签，多中心，全局阶段2研究PD-L1低/负复发或转移性头部和颈鳞状细胞癌：CONDOR
4. Initial Salvage Therapy for Patients with Advanced Germ Cell Tumors: Do We Need a Randomized Trial? [C] . Darren R. Feldman Genitourinary Cancers Symposium . 2012

机译：初始救生患者患者治疗晚期胚芽细胞肿瘤：我们需要随机试验吗？
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase III randomized open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC [O] . Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, 2015

机译：晚期转移性NSCLC患者一线治疗中的durvalumab（MEDI4736）联合tremelimumab或durvalumab单独与铂类化疗联合进行的III期随机开放标签研究：MYSTIC
7. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC [O] . Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, 2015

机译：晚期，转移性NSCLC患者一线治疗中的durvalumab（MEDI4736）联合tremelimumab或durvalumab单独与铂类化疗联合进行的III期随机开放标签研究：MYSTIC

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

著录项

相似文献

相关主题

期刊订阅